Product Description
DF-9001 is an immunotherapy agent targeting NK cells. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05597839)
Mechanisms of Action: EGFR Inhibitor,NK
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dragonfly Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Head and Neck Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DF9001-001 | P2 |
Recruiting |
Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Renal Cell Carcinoma |
2025-08-01 |
3% |
2024-05-17 |
Primary Endpoints |